NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) released its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. The biopharmaceutical company earned $1.10 million during the quarter, compared to the consensus estimate of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

8 brokerages have issued 12 month price objectives for Kindred Biosciences' shares. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' stock price to reach $14.44 in the next year. This suggests a possible upside of 52.0% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

News coverage about KIN stock has been trending very negative on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kindred Biosciences earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a drop in short interest in December. As of December 13th, there was short interest totalling 671,100 shares, a drop of 5.5% from the November 28th total of 709,900 shares. Based on an average daily trading volume, of 98,200 shares, the days-to-cover ratio is presently 6.8 days. Approximately 1.8% of the shares of the company are sold short. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Theravance Biopharma (TBPH), Innoviva (INVA), Esperion Therapeutics (ESPR), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL) and IGM Biosciences (IGMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $9.50.

Kindred Biosciences has a market capitalization of $371.36 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

The official website for Kindred Biosciences is http://kindredbio.com/.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]